Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nicotine pouches may quiet the Brain's craving for cigarettes

NCT ID NCT07698470

Disease control Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study looks at whether a single 6 mg oral nicotine pouch can lower cigarette cravings and dampen brain activity triggered by smoking-related images. Adults who smoke and are moderately to highly dependent on nicotine will use the pouch after going without nicotine overnight. Researchers will measure changes in craving and prefrontal brain responses using a light-based brain scanner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral nicotine pouch (6 mg)
What this could lead to
If it works, this could support oral nicotine pouches as a harm-reduction tool to help adults who smoke reduce cigarette cravings.
What could go wrong
This is a small, early-stage study with only 45 participants, so results may not apply broadly. The effect is measured over a single session, not long-term quitting success.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 21 years - 55 years * Self-reported use of cigarettes within the past 30 days * Biochemical confirmation of cigarette use: o Carbon monoxide (CO) breath sample ≥10 ppm * Fagerström Test for Nicotine Dependence (FTND) score ≥5, indicating moderate to high nicotine dependence * Fluent in English * Willing to try an oral nicotine pouch * Willing to abstain from nicotine for at least 12 hours prior to each experimental session Exclusion Criteria: * Age younger than 21 years or older than 55 years * Biochemical evidence inconsistent with recent cigarette use: o CO breath sample \<10 ppm * Expressed intent to reduce or quit nicotine use within the next 30 days * History of medical conditions contraindicated for nicotine use (e.g., uncontrolled hypertension, recent cardiac events) * Primary use of non-cigarette products (e.g., cigars, pipe tobacco, smokeless tobacco) * Prior use of oral nicotine products in their lifetime

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nicotine dependence are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Harm Reduction nicotine dependence Smoking

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nicotine dependence

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Southern California - 3641 Watt Way (HNB B22)

    RECRUITING

    Los Angeles, California, 90089, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.